Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

POC products

Financiado

A novel microfluid based modular system to address POC challenges within the fie...

A novel microfluid based modular system to address POC challenges within the field of coagulation and hemostasis The New Oral Anticoagulants (NOACs) are widely advertised, with CAGR 15%/year, as they lack the necessity for monitoring of the patient. It is now corrected by increased levels of renal failure and hemorrhagic events. The project... ver más

31/12/2015

ILINE MICROSYSTEMS

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

ILINE MICROSYSTEMS Desarrollo y fabricacion de dispositivos medicos de diagnostico in-vitro, para diagnostico rapido, autodiagnostico y autocontrol. desarrollo...

TRL 5-6 | 2M€

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2015-12-31

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

PHC-12-2015-1: Clinical research for the validation of biomarkers and/or diagnostic medical devices

I+D

Cerrada hace 9 años

0% 70% 100%

1 Participantes

ILINE MICROSYSTEMS

50.00K€ | Lider

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 6 meses Fecha Inicio: 2015-06-02
Fecha Fin: 2015-12-31

Líder del proyecto

ILINE MICROSYSTEMS

TRL 5-6 | 2M€

Presupuesto del proyecto 71K€

Descripción del proyecto The New Oral Anticoagulants (NOACs) are widely advertised, with CAGR 15%/year, as they lack the necessity for monitoring of the patient. It is now corrected by increased levels of renal failure and hemorrhagic events. The project is focused on the validation and industrialization of new IVD POC device that will provide solutions to monitor low molecular weight heparin and NOACs which are not monitored by any existing POC systems. The proposed solution is improving patient care and management and lowering the increasing cost of centralized patient management related to the ageing of the population. This opens a business opportunity for our company since no POC device exists capable of performing similar diagnostic. Our solution has no direct competitors worldwide. The expected outcome is a complete diagnostic system based on proprietary microfluidic Core Technology patented by iLine Microsystems. This will extend the diagnostic range of the POC anticoagulation therapies that now can only be reached by multistep reactions run in centralized labs and accelerate the development of future tests. The feasibility study will focus on the business plan. Market size and niches can be measured for NOACs and their use in patient’s management. Both new lines of product are aiming at distinct market segments, emergencies, hospital tests or independent laboratories. Commercialization will follow the established strategy of sales via worldwide distributors. This approach eliminates the market entry barrier in hospitals and health care. We are building the clinical network including KOLs in the fields of hematology, cardiology and Critical Care where majority of the NOACs are prescribed and monitoring is vital. The proposed solution, due to its modular design and flexibility, has the unique potential for customization and improvements. The modular platform, create the possibility to diversify the markets and design products based on biomarkers outside of hemostasis and coagulation.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores